Emerging vaccine nanotechnology

Emerging vaccine nanotechnology
Graphical abstract. Credit: Acta Pharmaceutica Sinica B (2022). DOI: 10.1016/j.apsb.2021.12.021

In this new article publication from Acta Pharmaceutica Sinica B, researchers discuss emerging vaccine nanotechnology.

Looking retrospectively at the development of humanity, vaccination is an unprecedented medical landmark that saves lives by harnessing the human immune system. During the ongoing coronavirus disease 2019 (COVID-19) pandemic, vaccination is still the most effective defense modality.

The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights promising future of nanotechnology in vaccine development. Compared with conventional vaccines, nanovaccines are supposed to have advantages in lymph node accumulation, antigen assembly, and antigen presentation.

They also have unique pathogen biomimicry properties because of a well-organized combination of multiple immune factors. Beyond , vaccine nanotechnology also exhibits considerable potential for . The ultimate goal of cancer vaccines is to fully mobilize the potency of the immune system as a living therapeutic to recognize and eliminate , and nanotechnologies have the requisite properties to realize this goal.

In this review, the authors summarize the recent advances in vaccine nanotechnology from infectious disease prevention to cancer immunotherapy and highlight the different types of materials, mechanisms, administration methods, as well as future perspectives.

More information: Chan Feng et al, Emerging vaccine nanotechnology: From defense against infection to sniping cancer, Acta Pharmaceutica Sinica B (2022). DOI: 10.1016/j.apsb.2021.12.021

Provided by Compuscript Ltd

Citation: Emerging vaccine nanotechnology (2022, June 2) retrieved 14 April 2024 from https://phys.org/news/2022-06-emerging-vaccine-nanotechnology.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Vaccines from BioNTech/Pfizer and Moderna can be combined


Feedback to editors